Biogen Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBiogen Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 73), indicating performance broadly in line with the market. Earnings growth of 31% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $196.01 | +1.89% | ABOVE |
| 50 SMA | $190.93 | +4.60% | ABOVE |
| 100 SMA | $188.60 | +5.89% | ABOVE |
| 150 SMA | $184.21 | +8.42% | ABOVE |
| 200 SMA | $174.99 | +14.13% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BIIB in an uptrend right now?
BIIB has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BIIB is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BIIB overbought or oversold?
BIIB's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is BIIB outperforming the market?
BIIB has a Relative Strength (RS) Rating of 73 out of 99. BIIB is performing about average compared to the market.
Where is BIIB in its 52-week range?
BIIB is trading at $199.71, which is 97% of its 52-week high ($205.97) and 93% above its 52-week low ($121.05).
How volatile is BIIB?
BIIB has a Beta of 0.35 and 52-week volatility of 33%. It's less volatile than the S&P 500 - generally more stable.